It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP Quick QuoteCRSP - Free Report) . Shares have added about 7.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for CRISPR Therapeutics AG before we dive into how investors and analysts have reacted as of late.

Q2 Earnings & Sales Beat Estimates

CRISPR incurred a second-quarter 2026 loss of 94 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had incurred a loss of $2.40 in the year-ago quarter.

Total revenues were $10.2 million in the second quarter (comprising $10 million in collaboration revenue and the remainder from grant revenue), beating the Zacks Consensus Estimate of $7 million. In the year-ago period, CRISPR Therapeutics had recorded total revenues of $0.9 million, which comprised only grant revenues.

Vertex recorded Casgevy sales of $76 million in the second quarter of 2026. Sales increased 78% sequentially and 151% year over year, reflecting continued commercial uptake.

Controls Quarterly Costs

Research and development expenses were $67.2 million in the second quarter, down 3.9% year over year. The decline primarily reflected lower employee and facility-related expenses, partly offset by higher license fees.

General and administrative expenses declined 6.9% to $17.6 million, mainly due to lower employee-related costs, including stock-based compensation.

Collaboration expense, net, fell 10.8% to $40.3 million, due to an increase in CRISPR Therapeutics’ share of Casgevy revenues under the Vertex collaboration economics.

Acquired in-process research and development expenses were $2.5 million compared with $96.3 million in the year-ago quarter. The prior-year amount reflected costs related to the company’s agreement with Sirius Therapeutics.

How Have Estimates Been Moving Since Then?

Since the earnings release, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 10.46% due to these changes.

VGM Scores

At this time, CRISPR Therapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the fifth quintile for value investors.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, CRISPR Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

CRISPR Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Illumina (ILMN Quick QuoteILMN - Free Report) , has gained 2% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Illumina reported revenues of $1.16 billion in the last reported quarter, representing a year-over-year change of +9.4%. EPS of $1.31 for the same period compares with $1.19 a year ago.

For the current quarter, Illumina is expected to post earnings of $1.38 per share, indicating a change of +3% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Illumina. Also, the stock has a VGM Score of C.